51440-58-5

Upstream product

• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 99-75-2 4-methyl-benzoic acid methyl ester 

Downstream Products

• 345964-76-3 1-Bromo-4-(1-methoxycyclopropyl)-benzene 
• 1196450-13-1 1-tert-butyldiphenylsiloxy-5-(4-bromophenyl)-5-methoxycyclopent-1-ene 
• 1401226-83-2 (Z)-2-(4-bromophenyl)-2-methoxy-1-(triisopropylsiloxymethylidene)cyclobutane 
• 1401226-82-1 (E)-2-(4-bromophenyl)-2-methoxy-1-(triisopropylsiloxymethylidene)cyclobutane 
• 1401226-95-6 5-(4-bromophenyl)-5-methoxy-1-(triisopropylsiloxy)cyclopent-1-ene 

Relevant academic research and scientific papers

Organophosphazenes 27: The synthesis and polymerization of (4-ethenylphenyl)pentafluorocyclotriphosphazene

The synthesis and homopolymerization of a fluorocyclotriphosphosphazene with a directly bonded styrene moiety is presented. A multistep sequence was employed wherein commercially available p-bromostyrene is first converted to 1-(4-bromophenyl)-1-methoxyethene, 4-BrC6H4C(OCH3)CH2 which in turn is lithiated and added to N3P3F6 to give (4-(1-methoxyethenyl)phenyl)pentafluorocyclotri phosphazene, N3P3F5(4-C6H4C(OCH3)CH2)(2). Addition of tri(n-butyl)tin hydride to 2 followed by elimination of tri(n-butyl)tin methoxide over silica produced the target monomer, (4-ethenylphenyl)-pentafluorocyclotriphosphazene, and N3P3F5(4-C6H4CHCH2)(3). The new phosphazene derivatives were characterized by mass spectrometry, NMR (1H,13C,19F,31P) and IR spectroscopy. Radical addition polymerization of 3 resulted in the formation of poly(p-pentafluorocyclotriphosphazenylstyrene)(4). Molecular weights of the new polymer were determined by GPC and membrane osmometry. The GPC data suggested the occurrence of chain transfer in the polymerization. TGA studies showed that 4 exhibits high thermal stability compared to other organophosphazene polymers. The Tg value is significantly greater than that of polystyrene.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 8 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 2 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI

Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.